Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NGM BIOPHARMACEUTICALS, INC.

(NGM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about NGM BIOPHARMACEUTICALS, INC.
01/20NGM Bio to Participate in Upcoming Investor Conferences
AQ
01/10NGM BIOPHARMACEUTICALS : Bio Corporate Presentation January 2022
PU
01/10NGM BIOPHARMACEUTICALS : Bio - JPM 2022 Presentation
PU
01/10NGM Bio Outlines 2022 Strategic Priorities Across Its Portfolio of Clinical-Stage Oncol..
AQ
01/07Piper Sandler Adjusts Price Target on NGM Biopharmaceuticals to $32 From $30, Maintains..
MT
01/06NGM Bio to Present at 40th Annual J.P. Morgan Healthcare Conference
AQ
2021NGM Bio Announces Clinical Trial Collaboration with Merck Related to Ongoing Phase 1/2 ..
AQ
2021NGM Enters into Collaborative Agreement with Merck for Phase 1/2 Study of NGM707 with K..
MT
2021NGM Bio Announces Clinical Trial Collaboration with Merck Related to Ongoing Phase 1/2 ..
AQ
2021NGM Biopharmaceuticals, Inc. Announces Clinical Trial Collaboration with Merck Related ..
CI
2021NGM Bio to Participate in Upcoming Investor Conferences
GL
2021NGM BIOPHARMACEUTICALS : Q3 Earnings Snapshot
AQ
2021NGM Bio Provides Business Highlights and Reports Third Quarter 2021 Financial Results -..
PU
2021NGM Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Mo..
CI
2021NGM Bio Provides Business Highlights and Reports Third Quarter 2021 Financial Results
AQ
2021NGM BIOPHARMACEUTICALS : BMO Capital Raises Price Target on NGM Biopharmaceuticals to $35 ..
MT
2021NGM BIOPHARMACEUTICALS : Bio Presents Preliminary Findings from Ongoing Phase 1a/1b Dose E..
AQ
2021NGM Biopharmaceuticals, Inc. Presents Preliminary Findings from Ongoing Phase 1A/1B Dos..
CI
2021NGM BIOPHARMACEUTICALS : Stock Climbs After Raymond James Upgrade
MT
2021NGM BIOPHARMACEUTICALS : Raymond James Upgrades NGM Biopharmaceuticals to Strong Buy From ..
MT
2021NGM BIOPHARMACEUTICALS : B. Riley Raises NGM Biopharmaceuticals' PT to $35 from $32 Ahead ..
MT
2021NGM BIOPHARMACEUTICALS : Developing NGM831 to Treat Cancer
MT
2021NGM BIOPHARMACEUTICALS : Bio Discloses Fourth Oncology Development Candidate, 831, an ILT3..
AQ
2021NGM Biopharmaceuticals, Inc. Discloses Fourth Oncology Development Candidate, NGM831, a..
CI
2021NGM BIOPHARMACEUTICALS : BMO Capital Adjusts NGM Biopharmaceuticals' Price Target to $29 F..
MT
2021NGM BIOPHARMACEUTICALS : Goldman Sachs Adjusts NGM Biopharmaceuticals' Price Target to $25..
MT
2021NGM BIOPHARMACEUTICALS : Cowen Adjusts NGM Biopharmaceuticals' Price Target to $32 From $2..
MT
2021NGM BIOPHARMACEUTICALS : Piper Sandler Adjusts Price Target on NGM Biopharmaceuticals to $..
MT
2021NGM BIOPHARMACEUTICALS : Q2 Earnings Snapshot
AQ
2021NGM BIOPHARMACEUTICALS : Bio Provides Business Highlights and Reports Second Quarter 2021 ..
AQ
2021Ngm Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June..
CI
2021NGM BIOPHARMACEUTICALS : Chardan Suspends Coverage on NGM Biopharmaceuticals at Buy Rating..
MT
2021NGM BIOPHARMACEUTICALS : Announces Completion of Enrollment in Phase 2 CATALINA Study of 6..
AQ
2021NGM Announces Completion of Enrollment in Phase 2 CATALINA Study of NGM621 in Patients ..
CI
2021NGM BIOPHARMACEUTICALS : Doses First Patient in Study Evaluating Potential Cancer Drug
MT
2021NGM Bio Announces Initiation of Phase 1/2 Clinical Study of NGM707 for the Treatment of..
GL
2021NGM Biopharmaceuticals, Inc. Announces Initiation of Phase 1/2 Clinical Study of NGM707..
CI
2021NGM BIOPHARMACEUTICALS : Amends Partnership With Merck to Focus on Retinal, Cardiovascular..
MT
2021NGM BIOPHARMACEUTICALS : Amended and Restated Research Collaboration, Product Development ..
PU
2021NGM Amends Collaboration with Merck to Focus Primarily on Advancing Novel Medicines for..
GL
2021NGM Bio to Present at Two Upcoming Investor Conferences
GL
2021ONGOING INVESTIGATION ALERT : The Schall Law Firm Announces it is Investigating Claims Aga..
PR
2021NGM BIOPHARMACEUTICALS : BMO Capital Adjusts Price Target on NGM Biopharmaceuticals to $20..
MT
2021NGM BIOPHARMACEUTICALS : B. Riley Lowers NGM Biopharmaceuticals' PT to $25 from $41 After ..
MT
2021INVESTIGATION REMINDER : The Schall Law Firm Announces it is Investigating Claims Against ..
BU
2021Today on Wall Street: Tech stocks’ return as inflation fears ease
2021TODAY'S ANALYST RECOMMENDATIONS : Deere, Endeavor, Just Eat, Royal Mail, Visa...
2021Virgin Galactic, Ormat Technologies rise; Cimarex, NGM fall
AQ
2021SECTOR UPDATE : Health Care Stocks Still Narrowly Higher in Late Regular-Hours Trade
MT
2021INVESTIGATION ALERT : The Schall Law Firm Announces it is Investigating Claims Against NGM..
BU
2021UPDATE : NGM Bio Drops Aldafermin Liver Disease Drug After Trial Failure, Shares Slump 40%
MT
2021SECTOR UPDATE : Health Care Stocks Higher in Moderation
MT
2021NGM BIOPHARMACEUTICALS : Raymond James Downgrades NGM Biopharmaceuticals to Outperform Fro..
MT
2021NGM BIOPHARMACEUTICALS : to End Development of Liver Disease Drug Candidate After Clinical..
MT
2021NGM BIOPHARMACEUTICALS : Topline NASH Phase 2b ALPINE 2/3 Trial Results Presentation
PU
2021SECTOR UPDATE : Health Care Stocks Trade Higher Premarket Monday
MT
2021SECTOR UPDATE : Health Care
MT
2021NGM BIOPHARMACEUTICALS : Bio Says Study of Liver Disease Drug Candidate Aldafermin Failed ..
MT
2021NGM BIOPHARMACEUTICALS : Bio Reports Topline Results from 24-Week Phase 2b ALPINE 2/3 Stud..
PU
2021NGM Biopharmaceuticals, Inc. Reports Topline Results from 24-Week Phase 2B Alpine 2/3 S..
CI
2021NGM Bio Reports Topline Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in..
GL
2021NGM Bio to Host Conference Call to Discuss Topline Results from 24-Week Phase 2b ALPINE..
GL
2021NGM BIOPHARMACEUTICALS : Q1 Earnings Snapshot
AQ
2021NGM Bio Provides Business Highlights and Reports First Quarter 2021 Financial Results
GL
2021Ngm Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March..
CI
2021NGM Biopharmaceuticals, Inc. Announces Director Resignations
CI
2021NGM Announces Nomination of Roger M. Perlmutter for Election to Its Board of Directors
GL
2021Certain Stock Options of NGM Biopharmaceuticals, Inc. are subject to a Lock-Up Agreemen..
CI
2021Certain Common Stock of NGM Biopharmaceuticals, Inc. are subject to a Lock-Up Agreement..
CI
2021NGM BIOPHARMACEUTICALS : Raymond James Adjusts Price Target on NGM Biopharmaceuticals to $..
MT
2021NGM BIOPHARMACEUTICALS : Chardan Adjusts Price Target on NGM Biopharmaceuticals to $44 Fro..
MT
2021NGM BIOPHARMACEUTICALS : Q4 Earnings Snapshot
AQ
2021Ngm Biopharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended Dece..
CI
2021NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2020 Fina..
GL
2021NGM BIOPHARMACEUTICALS : Biopharma Starts Phase 1b Study of 120 in Patients with Metastati..
MT
1  2  3Next
Upcoming event on NGM BIOPHARMACEUTICALS, INC.